Evaluating the effect of L-carnitine on the prevention of postoperative atrial fibrillation and acute kidney injury (AKI) following coronery artery bypass grafting (CABG) surgery.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201301028698N7

Enrollment

100

Registered

2013-04-10

Start date

2013-02-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic heart disease. Atherosclerotic heart disease

Interventions

Intervention 1: Intervention group: administration of L-carnitine, 1 g oral solution vial, 3 times a day (TDS) every 8 hours, duration of intervention is 4 days (from 48 hours before surgery until 48

Treatment - Drugs

Intervention group: administration of L-carnitine, 1 g oral solution vial, 3 times a day (TDS) every 8 hours, duration of intervention is 4 days (from 48 hours before surgery until 48 hours after it)

Control group: This group does not receive any interventions.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ]Inclusion criteria: The patients who candidate for Coronary artery bypass graft surgery in Tehran Heart center are selected by simple randomised method; There are not any limitations for age; and sex in this study. Exclusion criteria: Valvular surgery; History of supraventricular arrhythmia; History of siezure; History of hypersensitivity reaction to l-carnitine; Chronic liver failure (Liver enzymes more than 3 times of ULN); Chronic kidney disease (Stage IV & V); Hypothyroidism; Use of Magnesium, NSAIDs and Antiarrhythmic medication.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Atrial fibrillation. Timepoint: 5 days post CABG surgery. Method of measurement: ECG, hs-CRP.	—

Secondary

Measure	Time frame
Acute kidney injury. Timepoint: up to 48 hours after surgery. Method of measurement: NGAL, serum creatinine.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzita Hajhossein Talasaz

Tehran University of Medical Sciences

atalasaz@razi.tums.ac.ir+98 21 6695 4709

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026